Logo image of DMTK

DERMTECH INC (DMTK) Stock Fundamental Analysis

NASDAQ:DMTK - Nasdaq - US24984K1051 - Common Stock - Currency: USD

0.094  -0.01 (-11.32%)

After market: 0.095 +0 (+1.06%)

Fundamental Rating

2

DMTK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. DMTK may be in some trouble as it scores bad on both profitability and health. DMTK is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DMTK has reported negative net income.
In the past year DMTK has reported a negative cash flow from operations.
DMTK had negative earnings in 4 of the past 5 years.
In the past 5 years DMTK always reported negative operating cash flow.
DMTK Yearly Net Income VS EBIT VS OCF VS FCFDMTK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

DMTK has a worse Return On Assets (-87.04%) than 73.69% of its industry peers.
With a Return On Equity value of -224.09%, DMTK is not doing good in the industry: 71.95% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.04%
ROE -224.09%
ROIC N/A
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
DMTK Yearly ROA, ROE, ROICDMTK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 8.51%, DMTK is in the better half of the industry, outperforming 74.22% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for DMTK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMTK Yearly Profit, Operating, Gross MarginsDMTK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

DMTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DMTK has been increased compared to 1 year ago.
DMTK has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, DMTK has an improved debt to assets ratio.
DMTK Yearly Shares OutstandingDMTK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
DMTK Yearly Total Debt VS Total AssetsDMTK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -8.44, we must say that DMTK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.44, DMTK is doing worse than 73.69% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that DMTK is not too dependend on debt financing.
DMTK has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: DMTK outperforms 49.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.44
ROIC/WACCN/A
WACC10.37%
DMTK Yearly LT Debt VS Equity VS FCFDMTK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 3.53 indicates that DMTK has no problem at all paying its short term obligations.
The Current ratio of DMTK (3.53) is worse than 61.85% of its industry peers.
DMTK has a Quick Ratio of 3.46. This indicates that DMTK is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.46, DMTK is not doing good in the industry: 61.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 3.46
DMTK Yearly Current Assets VS Current LiabilitesDMTK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.77% over the past year.
DMTK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.80%.
The Revenue has been growing by 37.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.14%
Revenue 1Y (TTM)9.8%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Sales Q2Q%10.58%

3.2 Future

DMTK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.08% yearly.
Based on estimates for the next years, DMTK will show a small growth in Revenue. The Revenue will grow by 6.40% on average per year.
EPS Next Y35.19%
EPS Next 2Y15.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.8%
Revenue Next 2Y6.4%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DMTK Yearly Revenue VS EstimatesDMTK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
DMTK Yearly EPS VS EstimatesDMTK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DMTK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMTK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMTK Price Earnings VS Forward Price EarningsDMTK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMTK Per share dataDMTK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

DMTK's earnings are expected to grow with 15.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.08%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DMTK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DERMTECH INC

NASDAQ:DMTK (6/26/2024, 8:00:02 PM)

After market: 0.095 +0 (+1.06%)

0.094

-0.01 (-11.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2024-05-14/amc
Earnings (Next)08-01 2024-08-01/amc
Inst Owners1.25%
Inst Owner Change-99.05%
Ins Owners14.8%
Ins Owner Change0%
Market Cap3.29M
Analysts43.33
Price Target1.53 (1527.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.37%
Min EPS beat(2)2.83%
Max EPS beat(2)7.91%
EPS beat(4)4
Avg EPS beat(4)9.33%
Min EPS beat(4)0.28%
Max EPS beat(4)26.31%
EPS beat(8)7
Avg EPS beat(8)4.76%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-3.77%
Revenue beat(2)0
Avg Revenue beat(2)-5.25%
Min Revenue beat(2)-5.62%
Max Revenue beat(2)-4.87%
Revenue beat(4)1
Avg Revenue beat(4)-1.59%
Min Revenue beat(4)-5.62%
Max Revenue beat(4)5.68%
Revenue beat(8)2
Avg Revenue beat(8)-4.65%
Revenue beat(12)3
Avg Revenue beat(12)-4.35%
Revenue beat(16)7
Avg Revenue beat(16)3.66%
PT rev (1m)-26.59%
PT rev (3m)-46.43%
EPS NQ rev (1m)-10.64%
EPS NQ rev (3m)-0.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)-7.64%
Revenue NQ rev (3m)-8.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.21
P/FCF N/A
P/OCF N/A
P/B 0.08
P/tB 0.08
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.12
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-2.06
OCFYN/A
SpS0.45
BVpS1.14
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.04%
ROE -224.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.51%
FCFM N/A
ROA(3y)-57.34%
ROA(5y)-43.66%
ROE(3y)-99.56%
ROE(5y)-68.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.7%
Cap/Sales 0.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 3.46
Altman-Z -8.44
F-Score3
WACC10.37%
ROIC/WACCN/A
Cap/Depr(3y)174.84%
Cap/Depr(5y)226.26%
Cap/Sales(3y)17.22%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.14%
EPS Next Y35.19%
EPS Next 2Y15.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.8%
Revenue growth 3Y37.45%
Revenue growth 5YN/A
Sales Q2Q%10.58%
Revenue Next Year16.8%
Revenue Next 2Y6.4%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.62%
EBIT Next 3Y9.65%
EBIT Next 5YN/A
FCF growth 1Y9.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.43%
OCF growth 3YN/A
OCF growth 5YN/A